Chikungunya Vaccines Market Size, Share, and Industry Analysis, By Type (Live-Attenuated Virus Vaccines, Inactivated Viral Vaccines, and Others), By Age Group (Pediatric and Adult), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Regional Forecast, 2025-2032

Chikungunya is a viral disease transmitted by mosquitoes carrying the chikungunya virus. It typically presents with an abrupt onset of fever and is often accompanied by joint pain. Additional symptoms include muscle pain, headache, fatigue, nausea, and skin rash along with other symptoms. Although the intense joint pain typically subsides within a few days, it can remain for an extended period, lasting months to even years.

To reduce fever and pain caused by chikungunya, sufficient rest, fluids, or over-the-counter (OTC) pain medicines such as paracetamol are used. Apart from some OTC medicines, such as paracetamol, that provide symptomatic relief, there is no single medicine currently available in the market that is specifically approved for the treatment of chikungunya. However, by the end of 2023, the first vaccine was approved by the U.S. FDA for the treatment of chikungunya. This vaccine is expected to be available in the market by 2024.

The growing incidence of chikungunya across the world prompted pharmaceutical companies to be involved in research activities to develop vaccines for chikungunya. This is one of the key factors contributing to the global market growth.

• For example, as per data provided by the European Centre for Disease Prevention and Control, nearly 70,000 chikungunya virus disease cases and 15 deaths have been reported across the world, as of February 2024.

Furthermore, the growing awareness about the disease and increasing government initiatives to control outbreaks and mitigate the economic burden of the disease are some of the additional factors driving the market growth.

The COVID-19 pandemic had a negative impact on the global chikungunya vaccines market in 2020. This was mainly due to the fact that several market players were focusing more toward the development of COVID-19 vaccines rather than vaccines for chikungunya.

Key Insights

The following key insights will be covered in the report:

• Prevalence of Chikungunya, By Key Regions/Countries, 2022/2023
• Pipeline Analysis, By Key Players
• Key Industry Developments - Mergers, Acquisitions & Partnerships
• Impact of COVID-19 on the Global Chikungunya Vaccines Market

Segmentation

Analysis by Type

Based on type, the market can be segmented into live-attenuated virus vaccines, inactivated viral vaccines, and others.

The live-attenuated virus vaccines segment held a majority of the market share in 2023. Live attenuated vaccines provide long-lasting and rapid immunity as compared to inactivated vaccines, which is a key factor driving the segment growth. Increasing initiatives by key industry players for the development of vaccines and receiving regulatory approvals for the products are some of the other factors supporting the segment growth during the forecast period.

• For instance, in November 2023, the U.S. FDA approved the first vaccine named as Ixchiq for the treatment of Chikungunya. This vaccine is a live attenuated vaccine and is administered as a single dose by injection into the muscle.

Furthermore, the inactivated viral vaccine segment is anticipated to grow at a significant growth rate over the coming years. Several research institutes have collaboratively initiated clinical trials for the inactivated viral vaccine development for Chikungunya, driving segment growth.

• For instance, in August 2021, the International Vaccine Institute and Bharat Biotech started a phase 2/3 clinical trial for the chikungunya vaccine in Costa Rica.

Furthermore, the others segment held a considerable market share in 2023, mainly due to increasing focus on the development of recombinant viral vaccines by key industry players.

Regional Analysis

Based on region, the chikungunya vaccine market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for a significant market share in 2023 and is expected to exhibit significant CAGR throughout the forecast period. The regional growth is mainly due to the presence of some of the cases of chikungunya, ultimately increasing the demand for vaccines in the North American region. Along with this, a strong pipeline of vaccines under development by the operating players in the region further supports regional growth in the near future.

• For example, as per data provided by the Lancet Regional Health in January 2024, the chikungunya cases in North America constitute 0.3% (12,172 out of 3,684,554) of the total reported cases across the Americas.

Furthermore, the Europe region accounted for a considerable market share in 2023. The regional growth is primarily attributed to focus of key market players on receiving regulatory approvals to introduce their vaccines for the treatment of chikungunya.

• For instance, in October 2023, Valneva SE, a specialty vaccine company, revealed the filing of a marketing application with the European Medicines Agency seeking approval for their single-dose chikungunya vaccine candidate, VLA1553.

Key Players Covered

The report includes the profiles of key players such as Valneva SE, Auro Vaccines, Themis Bioscience GmbH (Merck & Co.), Bharat Biotech, and Bavarian Nordic.

Key Industry Developments

• In May 2022, Valneva SE announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.
• In January 2021, Valneva SE and Instituto Butantan finalized agreements to collaborate on the development, manufacturing, and distribution of Valneva's single-dose chikungunya vaccine, VLA1553, within low and middle-income nations.
• In October 2020, Valneva SE declared that the European Medicines Agency had granted Priority Medicines designation to its vaccine candidate, VLA1553.
• In September 2019, Themis Bioscience GmbH raised USD 432.9 million in a series D round to fund a phase III trial that could lead to the approval of the world's first vaccine for chikungunya infection.

In January 2018, Zydus Cadila entered into a collaboration with Takeda Pharmaceutical Company Limited to develop the chikungunya vaccine.